Valeant Pharmaceuticals (VRX) PT, Estimates Raised at Jefferies on Strong Q3
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Valeant Pharma (VRX) Reports Unsurprising Results Ahead of Dec. Meeting - FBR Capital
October 20, 2014 2:58 PM EDTFBR Capital affirms Valeant Pharma (NYSE: VRX) at Outperform with a price target of $148 following Q3 results reported today.
Analyst William Tanner noted the following key points from the quarter:3Q14 results what Valeant needed to show ahead of Special Meeting vote. Likely facing another attack from Allergan, we believe 3Q14 results may be more challenging to spin as evidence that the company's fundamentals are not strong and that the business model is flawed. One important general disclosure was that growth was driven more by volume than price, undercutting a potential argument... More
Valeant Pharma (VRX) Reports Q3 EPS of $2.11
October 20, 2014 7:03 AM EDTValeant Pharma (NYSE: VRX) reported Q3 EPS of $2.11, versus $1.43 reported last year. Revenue for the quarter came in at $2.06 billion, versus $1.54 billion reported last year.
Analysts were looking for EPS of $1.99.
Valeant sees FY14 cash EPS of $8.22 to $8.32 and Q4 EPS from $2.45... More
